X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TAS6417 (zipalertinib) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was engineered to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR.
Lead Product(s): CLN-081,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
Taiho has also completed its acquisition of Cullinan Oncology’s subsidiary, Cullinan Pearl Corp. (Cullinan Pearl) which has worldwide rights outside of Japan* to CLN-081/TAS6417.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: $405.0 million Upfront Cash: $275.0 million
Deal Type: Collaboration June 23, 2022
Details:
TAS6417 (CLN-081), is designed as a next-generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC).
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Under the agreement, Taiho will acquire Cullinan Oncology’s subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan* to CLN-081/TAS6417, EGFR exon20 non-small cell lung cancer (NSCLC) regulatory milestones.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: $405.0 million Upfront Cash: $275.0 million
Deal Type: Collaboration May 12, 2022
Details:
CLN-081 or TAS6417 is an orally available, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild type EGFR.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
CLN-081 was administered orally at dose levels including BID showed promising response durability previously observed in initial phase 1 patient cohort (n=13) with estimated median response duration > 15 months and median progression free survival of 12 months.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: CLN-081
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
CLN-081 is an orally available, irreversible epidermal growth factor receptor (EGFR) inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild type EGFR.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
CLN-081 is an orally available, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild type EGFR.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: CLN-081
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Zai Lab gets exclusive license for the development, manufacturing and commercialization of CLN-081 in Greater China. Zai Lab to lead development and commercialization of CLN-081 in Greater China.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: $231.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration December 28, 2020
Details:
The poster presentation will summarize the initial Phase 1 experience with CLN-081 up to the data cutoff of September 1, 2020, including data on 22 patients treated at dose levels ranging from 30-150 mg administered orally twice daily.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
